431 related articles for article (PubMed ID: 27197003)
1. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
3. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
[TBL] [Abstract][Full Text] [Related]
4. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
Siemens A; Rassekh SR; Ross CJD; Carleton BC
Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Chang VY; Wang JJ
Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
[TBL] [Abstract][Full Text] [Related]
6. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Hertz DL; Caram MV; Kidwell KM; Thibert JN; Gersch C; Seewald NJ; Smerage J; Rubenfire M; Henry NL; Cooney KA; Leja M; Griggs JJ; Rae JM
Pharmacogenomics; 2016 Feb; 17(3):231-40. PubMed ID: 26799497
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
9. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.
Linschoten M; Teske AJ; Cramer MJ; van der Wall E; Asselbergs FW
Circ Genom Precis Med; 2018 Jan; 11(1):e001753. PubMed ID: 29557343
[TBL] [Abstract][Full Text] [Related]
11. Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Leong SL; Chaiyakunapruk N; Lee SW
Sci Rep; 2017 Feb; 7(1):39. PubMed ID: 28232737
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients.
Nyangwara VA; Mazhindu T; Chikwambi Z; Masimirembwa C; Campbell TB; Borok M; Ndlovu N
Br J Clin Pharmacol; 2023 Jan; ():. PubMed ID: 36630266
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study.
Zolk O; von dem Knesebeck A; Graf N; Simon T; Hero B; Abdul-Khaliq H; Abd El Rahman M; Spix C; Mayer B; Elsner S; Gebauer J; Langer T
JMIR Res Protoc; 2022 Feb; 11(2):e27898. PubMed ID: 35175211
[TBL] [Abstract][Full Text] [Related]
14. An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Dionne F; Aminkeng F; Bhavsar AP; Groeneweg G; Smith A; Visscher H; Rassekh SR; Ross C; Carleton B
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29271558
[TBL] [Abstract][Full Text] [Related]
15. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR; Ross CJ;
Pharmacogenomics; 2015; 16(10):1065-76. PubMed ID: 26230641
[TBL] [Abstract][Full Text] [Related]
17. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.
Reichwagen A; Ziepert M; Kreuz M; Gödtel-Armbrust U; Rixecker T; Poeschel V; Reza Toliat M; Nürnberg P; Tzvetkov M; Deng S; Trümper L; Hasenfuss G; Pfreundschuh M; Wojnowski L
Pharmacogenomics; 2015; 16(4):361-72. PubMed ID: 25823784
[TBL] [Abstract][Full Text] [Related]
18. Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; González Font AE; Córdova Hurtado LP; Castañeda VL; Fierro IV; Romero LP; Reyes HA
Pharmacogenet Genomics; 2021 Jul; 31(5):108-115. PubMed ID: 34096893
[TBL] [Abstract][Full Text] [Related]
19. Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Magdy T; Jouni M; Kuo HH; Weddle CJ; Lyra-Leite D; Fonoudi H; Romero-Tejeda M; Gharib M; Javed H; Fajardo G; Ross CJD; Carleton BC; Bernstein D; Burridge PW
Circulation; 2022 Jan; 145(4):279-294. PubMed ID: 34874743
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
